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Abstract
Background: Commensal-derived probiotic bacteria inhibit enteric pathogens and regulate host
immune responses in the gastrointestinal tract, but studies examining specific functions of beneficial
microbes in the context of biofilms have been limited in scope.
Results: Lactobacillus reuteri formed biofilms that retained functions potentially advantageous to the
host including modulation of cytokine output and the production of the antimicrobial agent,
reuterin. Immunomodulatory activities of biofilms were demonstrated by the abilities of specific L.
reuteri  strains to suppress human TNF production by LPS-activated monocytoid cells.
Quantification of the antimicrobial glycerol derivative, reuterin, was assessed in order to document
the antipathogenic potential of probiotic biofilms. L. reuteri biofilms differed in the quantities of
reuterin secreted in this physiological state.
Conclusion:  L. reuteri biofilms secreted factors that confer specific health benefits such as
immunomodulation and pathogen inhibition. Future probiotic selection strategies should consider
a strain's ability to perform beneficial functions as a biofilm.
Background
Probiotics are defined by the Food and Agricultural
Organization of the United Nations as "live microorgan-
isms which when administered in adequate amounts con-
fer a health benefit on the host" [1,2]." The effectiveness
of probiotics is strain-specific, and each strain may con-
tribute to host health through different mechanisms. Pro-
biotics can prevent or inhibit the proliferation of
pathogens, suppress production of virulence factors by
pathogens, or modulate the immune response. L. reuteri is
a promising therapy for the amelioration of infantile
colic, alleviation of eczema, reduction of episodes of
workplace illness, and suppression of H. pylori infection
[3-9]. L. reuteri is considered an indigenous organism of
the human gastrointestinal tract and is present on the
mucosa of the gastric corpus, gastric antrum, duodenum,
and ileum [10,11].
Biofilms or adherent structured microbial communities in
the oral cavity and respiratory tract are well-characterized
and are associated with respiratory infections, dental car-
ies, and periodontitis [12,13]. In contrast, biofilm-like
communities of the gastrointestinal and female urogenital
tracts containing beneficial lactobacilli may have a protec-
tive role. In bacterial vaginosis, indigenous lactobacilli are
replaced with pathogenic biofilms consisting of Gard-
nerella vaginalis and other bacteria [6]. Probiotic L. reuteri
can displace G. vaginalis biofilms and could potentially re-
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establish protective biofilms in the female urogenital tract
[6]. Due to artifactual removal of biofilms by traditional
fixatives during specimen processing, studies of gastroin-
testinal biofilms are sparse. Using non-aqueous fixatives
and special techniques, several groups have documented
the presence of intestinal biofilms in the mammalian
intestine [14-17]. The bacterial composition of biofilm-
like communities in the mucus layer or the mucosa-asso-
ciated microbiota (MAM), differs from the composition
of the fecal microbiota, and the human MAM includes
lactobacilli [18-20]. Changes in the composition and
architecture of the MAM through diet or disease may affect
overall health status [20-24]. Denser biofilms were found
in patients with inflammatory bowel disease (IBD) when
compared to healthy controls, and 60% of the biofilm
mass was comprised of the commensal Bacteroides fragilis
[17]. These studies indicate a need to understand the con-
tributions of individual strains and species to the aggre-
gate function of gastrointestinal biofilms.
This report describes the ability of an established com-
mensal and probiotic organism, L. reuteri, to form bio-
films in vitro and perform potentially beneficial functions
as biofilms. Two basic probiotic functions that depend on
secreted factors were studied in the context of biofilms.
First, modulation of innate immunity was investigated by
studying regulation of human TNF production. In prior
studies, supernatants from planktonic L. reuteri cultures
reduced production of the pro-inflammatory cytokine,
TNF [25], and TNF suppression was important in alleviat-
ing inflammation in a murine model of IBD [26]. Probi-
otic L. reuteri biofilms have not been examined for TNF
inhibition. Secondly, production of the antimicrobial
compound  β-hydroxy-propionaldehyde, known as reu-
terin, was evaluated in order to assess anti-pathogenic
properties of L. reuteri biofilms.
Results
Probiotic Lactobacillus reuteri forms biofilms
Various human isolates of L. reuteri were grown in 96-well
polystyrene plates and retention of crystal violet was used
to assess relative biofilm densities (Fig. 1A). All strains of
L. reuteri adhered to polystyrene, but strains differed with
respect to relative densities as measured by absorbance
spectrophotometry. L. reuteri strains ATCC PTA 6475 and
ATCC PTA 5289 (OD570 was 3.92 and 3.17, respectively)
formed aggregates with greater optical densities than L.
reuteri strains ATCC 55730 and CF48-3A (OD570 was 1.10
and 1.44, respectively). The differences between strains
were also observed in cell counts. The bacterial densities
(CFU/cm2) in biofilms of ATCC PTA 6475 and ATCC PTA
5289 were roughly 10-fold greater than the bacterial den-
sities of ATCC 55730 and CF48-3A biofilms (Fig. 1B). L.
reuteri  biofilms were stained with acridine orange and
observed by confocal microscopy (Fig. 2). Monospecies
biofilms of ATCC 55730 were 7 μm (+/- 2 μm) thick. The
thickness of L. reuteri biofilms was assessed at 24 and 48
hours. No differences in biofilm thickness were observed.
Consistent with this study, other researchers demon-
strated formation of only thin biofilms (approximately 5
μm) when L. reuteri biofilms were cultured on plastic cou-
pons for 32 hours [27].
L. reuteri biofilms modulate human TNF production
To test the immunomodulatory properties of L. reuteri
biofilms, supernatants from the biofilms were added to
human monocytoid THP-1 cells in the presence and
absence of LPS. LPS was added to the THP-1 cells to stim-
ulate production of pro-inflammatory TNF by THP-1
cells. L. reuteri strains that produced TNF inhibitory fac-
tors as planktonic cultures (L. reuteri strains ATCC PTA
L. reuteri adherence is strain-dependent Figure 1
L. reuteri adherence is strain-dependent. L. reuteri bio-
films were cultured for 24 hours in 96-well polystyrene 
plates. The relative propensities of L. reuteri to form biofilms 
were measured by absorbance spectrophotometry after 
staining with crystal violet. L. reuteri ATCC 6475 and ATCC 
PTA 5289 were more adherent then CF48-3A and ATCC 
55730 (ANOVA, p < 0.02).
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
M
e
d
i
a
A
T
C
C
P
T
A
 
6
4
7
5
A
T
C
C
P
T
A
 
5
2
8
9
C
F
4
8
-
3
A
A
T
C
C
5
5
7
3
0
A
b
s
o
r
b
a
n
c
e
 
 
(
5
6
0
 
n
m
)
A
100000
1000000
10000000
100000000
1000000000
A
T
C
C
 
P
T
A
6
4
7
5
A
T
C
C
 
P
T
A
5
2
8
9
C
F
4
8
-
3
A
A
T
C
C
5
5
7
3
0
C
o
l
o
n
y
 
F
o
r
m
i
n
g
 
U
n
i
t
s
 
/
 
m
L
 B BMC Microbiology 2009, 9:35 http://www.biomedcentral.com/1471-2180/9/35
Page 3 of 9
(page number not for citation purposes)
6475 and ATCC PTA 5289, 76 and 77%, respectively)
(Fig. 3) demonstrated similar abilities to suppress TNF
production when cultured as biofilms (Fig. 4). When TNF
inhibitory factors were obtained directly from L. reuteri
biofilms grown in 24-well polystyrene plates, ATCC PTA
6475 and ATCC PTA 5289 also inhibited TNF production
by 60% and 50%, respectively, when compared to the
media control (Fig. 4A). Supernatants of L. reuteri ATCC
PTA 5289 biofilms cultured in a flow cell inhibited TNF
by 73% compared to the media control (Fig. 4B). L. reuteri
strains that did not suppress human TNF in planktonic
phase (ATCC 55730 and CF48-3A) (Fig. 3) lacked TNF-
inhibitory capabilities when supernatants were obtained
from the same strains cultured as biofilms (Fig. 4). Sur-
prisingly, supernatants from ATCC 55730 and CF48-3A
biofilms did not induce TNF production by THP-1 cells in
the absence of LPS (data not shown) as the supernatants
from planktonic cultures did (Fig 3). Interestingly, the
ability of probiotic L. reuteri to regulate human TNF pro-
duction is strain-specific, and strain-specific TNF inhibi-
tion was maintained whether L. reuteri strains were
cultured as planktonic cells or biofilms. The relative abili-
ties to suppress human TNF in monocytoid cells were
directly correlated with relative abilities to aggregate and
form biofilms on polystyrene surfaces (Fig. 1A).
L. reuteri cultured as planktonic cells and biofilms 
produced the antimicrobial factor, reuterin
Antimicrobial activities of L. reuteri were assessed by
examining supernatants of planktonic and biofilm cul-
tures for reuterin. Planktonic cells and biofilms of L. reu-
teri  produced reuterin, although differences in reuterin
production were evident among strains. Planktonic cul-
tures of ATCC PTA 6475, ATCC PTA 5289, ATTC 55730
and CF48-3A produced 51.2, 45.2, 225.9, and 230.3 mM
L. reuteri biofilms were observed by confocal microscopy Figure 2
L. reuteri biofilms were observed by confocal micros-
copy. Biofilms were cultured in a flow cell supplied with MRS 
for 48 hours at 37°C in ambient atmosphere. L. reuteri bio-
films (green) were stained with acridine orange and observed 
by confocal microscopy. A single optical section and the 
stacked optical sections of ATCC 55730 (A and B, respec-
tively) are shown at 630× magnification. These images are 
representative of 30 microscopic fields obtained in 3 inde-
pendent experiments.
A
B
y-axis
z-axis
x-axis 
Modulation of TNF production by L. reuteri is strain-depend- ent Figure 3
Modulation of TNF production by L. reuteri is strain-
dependent. Cell-free supernatants from stationary phase L. 
reuteri cultures (planktonic cells) were added to human 
monocytoid cells in the presence or absence of E. coli-
derived LPS (no LPS-black bars, LPS-gray bars). Quantitative 
ELISAs measured the amounts of human TNF produced by 
THP-1 cells. In the absence of LPS, supernatants from L. reu-
teri CF48-3A and ATCC 55730 stimulated TNF by human 
THP-1 cells, while supernatants from ATCC PTA 6475 and 
ATCC PTA 5289 did not induce TNF production. However, 
L. reuteri CF48-3A and ATCC 55730 did not suppress TNF 
production by LPS-activated cells, while PTA 6475 and 
ATCC PTA 5289 inhibited production of TNF by 76% and 
77% respectively, when compared to the media control 
(ANOVA, p < 0.001).
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of reuterin, respectively. When reuterin quantities were
normalized to initial CFU/mL, planktonic cultures of
ATCC PTA 6475 and ATCC PTA 5289 produced 2.32 and
2.3 mmol reuterin/1012  cells, respectively, and ATCC
55730 and CF48-3A produced 31.89 and 36.24 mmol
reuterin/1012 cells, respectively (Fig. 5). For biofilms cul-
tured in multiwell plates, the four wild type L. reuteri
strains ATCC PTA 6475, ATCC PTA 5289, ATTC 55730
and CF48-3A produced 26.8, 16.5, 19.1, and 22.1 mM of
reuterin, respectively. After normalization of reuterin
quantities to bacterial cell counts, ATCC PTA 6475, ATCC
PTA 5289, CF48-3A, and ATCC 55730 produced 6.61,
5.41, 43.4, and 53.94 mmol of reuterin/1012 cells, respec-
tively, when cultured as biofilms in multiwell plates (Fig.
6). Trends in reuterin production were consistent with
planktonic and biofilm cultures of ATCC PTA 6475 and
ATCC 5289 producing lower quantities of reuterin than
strains ATCC 55730 and CF48-3A. Interestingly, the rela-
tive abilities of L. reuteri strains to produce reuterin were
inversely correlated with relative abilities to aggregate and
adhere to polystyrene (Fig. 1A).
Previous studies indicated that planktonic cultures of
human-derived L. reuteri strains used in this study were
relatively resistant to the antimicrobial effects of reuterin
(10 mM), when compared to other bacterial species
including closely related lactobacilli [[29,43] and JK Spin-
L. reuteri strains proficient in biofilm formation suppress TNF  production Figure 4
L. reuteri strains proficient in biofilm formation sup-
press TNF production. Cell-free supernatants from L. reu-
teri biofilms cultured in 24-well plates (A) or flow cells (B) 
were added to human monocytoid cells in the presence of E. 
coli-derived LPS. Quantitative ELISAs measured the amounts 
of human TNF produced by THP-1 cells. As biofilms, TNF 
inhibitory strains (ATCC PTA 6475 and ATCC PTA 5289) 
retained their ability to suppress TNF produced by LPS-acti-
vated human monocytoid cells. L. reuteri ATCC PTA 6475 
and ATCC PTA 5289 biofilms cultured in 24-well plates (A) 
inhibited TNF by 60% and 50% respectively, (ANOVA, p < 
0.02). Supernatants of L. reuteri ATCC PTA 5289 cultured in 
a flow cell (B) inhibited TNF by 73% when compared to the 
media control (ANOVA, p < 0.0001).
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L. reuteri strains cultured as planktonic cells produce the anti- microbial compound, reuterin Figure 5
L. reuteri strains cultured as planktonic cells produce 
the antimicrobial compound, reuterin. Stationary phase 
planktonic cultures of L. reuteri were incubated anaerobically 
in a glycerol solution. Reuterin concentrations of the cell free 
supernatants were determined using a colorimetric assay and 
were normalized with respect to viable colony counts prior 
to the addition of glycerol. ATCC PTA 6475 and ATCC 5289 
produced less reuterin than ATCC 55730 and CF48-3A 
(ANOVA, p < 0.05).
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L. reuteri biofilms produce reuterin Figure 6
L. reuteri biofilms produce reuterin. L. reuteri biofilms 
were cultured in MRS for 48 hours at 37°C in ambient 
atmosphere in multiwell plates. In order to measure reuterin 
production, biofilms were incubated in the presence of glyc-
erol in anaerobic conditions. Reuterin concentrations were 
determined using a colorimetric assay and were normalized 
with respect to viable colony counts prior to the addition of 
glycerol. All L. reuteri biofilms produced detectable amounts 
of reuterin, although inter-strain differences were observed. 
ATCC PTA 6475 and ATCC 5289 produced less reuterin 
than ATCC 55730 and CF48-3A (ANOVA, p < 0.05).
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ler, unpublished data]. However, since the cell viabilities
of planktonic cultures decrease as reuterin accumulates
[28], the quantities of reuterin produced by planktonic
cultures were normalized to the initial CFU/mL. Reuterin
was detected after biofilms were incubated in glycerol for
1, 2, and 3 hours (data not shown). Cell viabilities of bio-
films after reuterin production exceeded 92% (data not
shown), indicating that the biofilms were relatively resist-
ant to the quantities of reuterin produced by L. reuteri bio-
films.
Discussion
Two hallmark features of probiotic function, modulation
of cytokine and reuterin production, were examined in
this study. Commensal-derived probiotic L. reuteri strains
formed biofilms, and thesebiofilms retained the probiotic
functions observed with planktonic cultures. Single spe-
cies biofilms composed of anti-inflammatory L. reuteri
strains ATCC PTA 6475 and ATCC PTA 5289 secreted fac-
tors that suppressed TNF production by LPS-activated
monocytoid cells. In contrast, biofilms comprised of
immunostimulatory probiotic strains ATCC 55730 and
CF48-3A lacked the ability to stimulate human TNF pro-
duction by human cells in the absence of LPS activation.
ATCC 55730 and CF48-3A produced greater quantities of
reuterin than ATCC PTA 6475 and ATCC PTA 5289 when
the bacteria were cultured as planktonic cells or biofilms.
Human breast milk-derived strains (ATCC PTA 6475 and
ATCC 55730) differed with respect to relative propensities
to form biofilms, and these strains demonstrated different
biological properties in the context of biofilms.
Lactic acid bacteria secrete factor(s) that inhibit cytokine
production by immune cells [26,29-31], and this report
established that probiotic biofilms cultured in a variety of
conditions produced factor(s) that suppress TNF produc-
tion by LPS activated human monocytes/macrophages.
Previous studies in this lab have demonstrated that the
TNF-inhibitory factors are detected in mid-log to station-
ary phase cultures [32]. Stationary phase cultures yield the
most consistent TNF-inhibitory activities (Y.P. Lin, per-
sonal communication). Modulation of the mucosal
immune system by intestinal commensal bacteria may
have important implications for immune homeostasis
and biofilm formation [33]. Intestinal bacteria such as L.
reuteri  may stimulate or suppress innate immune
responses via several mechanisms including modulation
of pro-inflammatory cytokines. L. reuteri strains in this
study can be divided into two subsets, immunosuppres-
sive (ATCC PTA 6475 and ATCC PTA 5289) and immu-
nostimulatory strains (ATCC 55730 and CF48-3A), and
each subset has potential therapeutic value. TNF inhibi-
tory strains of L. reuteri reduced inflammation in a H.
hepaticus-induced murine model of inflammatory bowel
disease [26]. By contrast, stimulation of the mucosal
innate immune system may be associated with enhanced
protection against enteric infections.
Interestingly, mucosal inflammation has been associated
with enhanced biofilm densities in the intestine [34,35].
The pro-inflammatory cytokine TNF promotes the prolif-
eration of E. coli, and secretory IgA increased agglutination
of  E. coli, an initial step in biofilm development
[34,36,37]. Although, these experiments were performed
with monospecies biofilms in vitro, the data raise ques-
tions regarding events that occur in complex microbial
communities  in vivo. When not attached to a surface,
immunostimulatory L. reuteri strains may stimulate host
immune responses and promote commensal biofilm for-
mation, particularly in neonates. When L. reuteri biofilms
are established, probiotic strains may have a diminished
ability to stimulate TNF, effectively suppressing the for-
mation of dense, complex multispecies biofilms in the
mucus layer. Because such complex, dense biofilms have
been associated with inflammation and disease [17], the
ability of probiotics to differentially regulate production
of immunomodulatory factors in the context of plank-
tonic and biofilm lifestyles may be an important probiotic
feature. Alternatively, the TNF stimulatory factor(s) may
be produced by L. reuteri biofilms and not detected in the
experimental conditions used in this study. In contrast to
immunostimulatory L. reuteri strains, anti-inflammatory
probiotics may form denser biofilms in vivo that thwart
pathogenic biofilm formation by preventing harmful
host:pathogen interactions and overgrowth of commensal
bacteria in the intestine. As an example of pathogen inhi-
bition, other lactobacilli suppressed the binding of Staphy-
lococcus aureus to epithelial cells [38].
Reuterin is a potent anti-pathogenic compound produced
by L. reuteri and capable of inhibiting a wide spectrum of
microorganisms including gram-positive bacteria, gram-
negative bacteria, fungi, and protozoa [39]. Maximum
reuterin production by L. reuteri occurs during late log and
stationary phase cultures (J.K. Spinler, personal commu-
nication). Reuterin and other anti-pathogenic factors may
be important for maintaining a healthy gut microbiota by
preventing intestinal overgrowth by other commensal and
pathogenic microorganisms. Recently, the addition of L.
reuteri ATCC 55730 or reuterin to the intestinal microbi-
ota was shown to reduce the E. coli population in an in
vitro fermentation model [40]. Thus, antimicrobial com-
pounds like reuterin may have a fundamental role in
shaping and modeling the composition and spatial archi-
tecture of the gastrointestinal microbiota. L. reuteri bio-
films produced reuterin, indicating that probiotic L.
reuteri may be protective against pathogens in either the
planktonic or biofilm state. Interestingly, strains that pro-
duce relatively high quantities of reuterin are immunos-
timulatory when cultured as planktonic cells. In vivo,BMC Microbiology 2009, 9:35 http://www.biomedcentral.com/1471-2180/9/35
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immunostimulation by L. reuteri may promote coloniza-
tion and biofilm formation of commensal lactobacilli,
and reuterin could prevent opportunistic bacteria from
establishing a niche. Hypothetically, once the immunos-
timulatory strains are established on the mucosal surface,
TNF stimulation is diminished, and higher quantities of
reuterin are produced. Elevated quantities of reuterin
adjacent to the mucosa may effectively alter surrounding
commensal microbial populations and prevent coloniza-
tion and adherence by pathogenic bacteria. Biofilms are
relatively resistant to several antimicrobial agents when
compared to planktonic cultures [41]. The enhanced
resistance of biofilms to antimicrobial compounds may
explain, in part, the resistance of L. reuteri biofilms to reu-
terin and elevated amounts of reuterin produced by these
biofilms, as described in this study.
While the growth conditions used for the flow cell and
planktonic cultures differed, similar probiotic activities by
each L. reuteri strain were observed. TNF inhibitory activi-
ties and reuterin production of L. reuteri were also consist-
ent when biofilms (in multiwell plates) and planktonic
cells were cultured using the same growth conditions.
Although these experiments were conducted with bio-
films grown in vitro on abiotic surfaces, biofilms with pro-
biotic function may be important for delivery of beneficial
effects in the mammalian host. A mutant strain of L.
crispatus, unable to bind mucus and adhere to the colonic
mucosa, did not have a protective effect in a murine colitis
model compared to the wild type aggregating strain even
when the bacteria were continuously supplied to mice
[42]. Mucus-binding ability may be important for probi-
otics to adhere to the mucosal surface and form biofilms
within the intestine. Defects in cell surface features may
affect biofilm formation and the abilities of probiotics to
persist and colonize the intestine in vivo. L. reuteri strain
100–23 deficient in alanylation of cell surface lipoteichoic
acids proliferated similarly to wild type cells as planktonic
bacteria, but failed to compete effectively and form com-
plex biofilms in vivo [43]. In the context of established
intestinal microbial communities, probiotic biofilms may
be more effective at long-term colonization and restoring
missing functions in disease states.
Conclusion
In conclusion, probiotic strategies for the prevention and
treatment of disease may require discovery and develop-
ment of strains that form effective biofilms. If biofilm for-
mation facilitates long-term colonization and persistence
in the intestine, biofilms that retain probiotic functions
may be important for sustained efficacy in vivo. The
human gastrointestinal microbiota is a complex ecosys-
tem that is shaped and maintained by multiple host and
microbial factors. Changes in the spatial distribution,
community architecture, or composition of the gastroin-
testinal microbiota may alter intestinal physiology and
immunity, including susceptibility to infection. Probiot-
ics in biofilm-like communities may be essential for long-
term remodeling of the composition and function of the
intestinal microbiome.
Methods
Key reagents, bacterial strains and mammalian cell lines
L. reuteri strains were grown in deMan, Rogosa, Sharpe
(MRS; Difco, Franklin Lakes, NJ) or LDMIIIG (pH 6.5)
(see Additional file 1) media. An anaerobic chamber
(1025 Anaerobic System, Forma Scientific, Waltham, MA)
supplied with a mixture of 10% CO2, 10% H2, and 80%
N2  was used for anaerobic culturing of lactobacilli.
Biogaia AB (Raleigh, NC) provided L. reuteri strains ATCC
PTA 6475, ATCC PTA 5289, ATCC 55730, and CF48-3A.
L. reuteri ATCC PTA 6475 and ATCC 55730 were isolated
from the breast milk of healthy Finnish and Peruvian
women, respectively. ATCC PTA 5289 is an oral isolate
from a healthy Japanese woman. CF48-3A was isolated
from the feces of a healthy Finnish child. THP-1 cells
(ATCC TIB-202) were maintained in RPMI 1640 supple-
mented with 10% fetal bovine serum (Invitrogen,
Carlsbad, CA) at 37°C and 5% CO2. All chemical reagents
were obtained from Sigma-Aldrich (St Louis, MO) unless
otherwise stated. Polystyrene 96- and 24-well plates for
biofilm and tissue culture studies were obtained from
Corning (Corning, NY). Filters with polyvinylidene fluo-
ride membranes (0.22 mm pore size) (Millipore, Bedford,
MA) were used for sterilization.
L. reuteri biofilm adherence studies
L. reuteri cultured in MRS media for 16–18 hours were
diluted 1:50 in MRS to a final volume of 200 μL in sterile
96-well polystyrene plates. Plates were incubated anaero-
bically at 35°C for 24 hours. Media and planktonic cells
were removed by aspiration and two washes with de-ion-
ized water. Adherent cells were stained with crystal violet
(0.1% w/v) for 15 minutes at 37°C, 200 rpm. Crystal vio-
let was discarded and the plates were washed with de-ion-
ized water. The crystal violet was redissolved with ethanol
and the OD570 was determined by absorbance spectro-
photometry using a Spectramax 340 PC384 (Molecular
Devices, Sunnyvale, CA).
Confocal imaging of L. reuteri biofilms
Glass flow cells with a volume of 7.7 mL (Stovall Inc.,
Greensboro, NC) were assembled according to the manu-
facturer's instructions and maintained at 37°C in ambient
atmosphere. As previously described, one mL of L. reuteri
(OD600 = 0.1 or 7 × 107 cells) was injected into the flow
cell [44]. L. reuteri were allowed to adhere to the glass sur-
face for an hour before being continuously supplied with
25% MRS (v/v) at 2 mL per minute. Cell counts verified
that the selected flow rate removed planktonic cells and
retained adherent bacteria on the surface of the flow cell.
After 48 hours, the flow cells were collected and washedBMC Microbiology 2009, 9:35 http://www.biomedcentral.com/1471-2180/9/35
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once with sodium phosphate buffer (50 mM) for 10 min-
utes at 37°C, 70 rpm. L. reuteri biofilms were stained with
acridine orange for imaging by confocal microscopy.
Preparation of cell-free supernatants from L. reuteri 
planktonic cultures for immunomodulation studies
For planktonic cells, 10 mL of LDMIIIG was inoculated
with  L. reuteri cultures (incubated 16–18 hrs) and
adjusted to OD600 = 0.1. Bacteria were incubated for 24
hours at 35°C in anaerobic conditions. Cells were pel-
leted (4000 × g, RT, 10 minutes) and discarded. Superna-
tants were filter-sterilized (0.22 μm pore size). Aliquots
were vacuum-dried and resuspended to the original vol-
ume using RPMI.
Preparation of cell-free supernatants from L. reuteri 
biofilms for immunomodulation studies
For biofilms grown in 24-well plates, L. reuteri cultures
(16–18 hrs of incubation) were diluted 1:100 in 1 mL of
MRS broth. Plates were incubated anaerobically for 24
hours at 35°C. Supernatants and planktonic cells were
removed by aspiration, and biofilms were washed with 50
mM sodium phosphate buffer (37°C, 100 rpm, 10 min-
utes). One mL of LDMIIIG was added to each well, and
the plates were incubated for 2 hours at 35°C in anaerobic
conditions. The supernatants were filter-sterilized (0.22
μm pore size), vacuum-dried and resuspended in RPMI to
the starting volume.
L. reuteri biofilms were cultured in flow cells supplied
with MRS media for the first 23 hours followed by immer-
sion in LDMIIIG at a flow rate of 2 mL per min in ambient
atmosphere at 37°C. Biofilm supernatants were collected
by sampling effluents, downstream from the chambers
containing the biofilms, at the flow cell's luer lock connec-
tion after 24 hours of culture. The supernatants were filter-
sterilized (0.22 μm pore size), vacuum dried, resuspended
to 1/20 the starting volume in RPMI, and tested for TNF
inhibition.
TNF inhibition experiments
As previously described [45], cell-free supernatants of L.
reuteri planktonic cell or biofilm cultures (5% v/v) and E.
coli  O127:B8 LPS (100 ng/mL) were added to human
THP-1 cells (approximately 5 × 104 cells). Plates were
incubated at 37°C and 5% CO2 for 3.5 hours. THP-1 cells
were pelleted (1500 × g, 5 minutes, 4°C), and TNF quan-
tities in monocytoid cell supernatants were determined by
quantitative ELISAs (R&D Systems, Minneapolis, MN).
Preparation of cell-free supernatants from L. reuteri 
planktonic cultures for reuterin quantification
Based on a previously described method [46], L. reuteri
cultures (16–18 hrs of incubation) were washed twice
with sodium phosphate buffer (50 mM Na2HPO4 and
NaH2PO4). The cells were then suspended in sterile 250
mM glycerol at 2.2 × 109 CFU/mL and incubated anaero-
bically at 35°C for 2 hours. Supernatants were filter-steri-
lized (0.22 μm pore size) and stored at 4°C before the
concentration of reuterin was determined. The quantities
of reuterin were determined using a colorimetric assay
previously described [46]. Briefly, serial dilutions of reu-
terin were made in sterile glycerol (250 mM). Forty μL of
each reuterin dilution were combined with 30 μL of tryp-
tophan (10 mM) in HCl (50 mM), and 120 μL of HCl (12
M). Under acidic conditions, tryptophan reacts with the
aldehyde of reuterin to form a β-carboline derivative that
oxidizes to yield a purple pigment. Plates were incubated
for 25 minutes at 37°C in ambient atmosphere, and the
OD560was determined using the Spectramax 340 PC384
(Molecular Devices, Sunnyvale, CA). Dilutions of HPLC-
quantified reuterin were used as standards. The amount of
reuterin produced was normalized to the initial CFU/mL
of the cultures.
Preparation of cell-free supernatants from L. reuteri 
biofilms for reuterin quantification
For biofilms grown in 12-well plates, L. reuteri cultures
(16–18 hrs of incubation) were diluted 1:100 in 2 mL of
MRS broth. Plates were incubated anaerobically for 24
hours at 35°C. Supernatants and planktonic cells were
removed by aspiration, and biofilms were washed with 50
mM sodium phosphate buffer (37°C, 100 rpm, 10 min-
utes). The wash buffer was aspirated, and 2 mL of sterile
250 mM glycerol were added. The plates were incubated
anaerobically at 35°C for 2 hours. Supernatants were fil-
ter-sterilized (0.22 μm pore size) and stored at 4°C before
the concentration of reuterin was determined. Reuterin
was produced and measured by methods described in the
previous section (adapted from [29]). Biofilms were
removed from multiwell plates by sonication (5 minutes,
20°C), and serial dilutions were plated to determine cell
counts. The quantities of reuterin were normalized to the
initial bacterial counts (bacterial cell numbers at the
beginning of each experiment) of biofilms cultured under
identical conditions.
Statistical analyses
All experiments were performed a minimum of three
times and analyzed using a single factor ANOVA test. Dif-
ferences were considered statistically significant if p <
0.05. All error bars in the figures represent standard devi-
ations.
Authors' contributions
SEJ designed and undertook all experiments described in
this manuscript. SEJ and JV drafted the manuscript. JV
conceived the study, supervised the research and secured
funding for this research. All authors have read and
approved the final manuscript.BMC Microbiology 2009, 9:35 http://www.biomedcentral.com/1471-2180/9/35
Page 8 of 9
(page number not for citation purposes)
Additional material
Acknowledgements
This work was supported by research funding to J.V. from the U.S. National 
Institutes of Health (DK065075 and AT003482) and the Crohn's & Colitis 
Foundation of America (CCFA). We also acknowledge the support of the 
Texas Medical Center Digestive Diseases Center (Public Health Service 
Grant DK56338). The authors acknowledge Barbara Trautner and Richard 
Atkinson for help with confocal microscopy analyses of biofilms, and 
Eamonn Connolly (Biogaia AB) for provision of L. reuteri strains. The 
authors also acknowledge Beverly Vispo and Ching Ou for assistance with 
reuterin quantification, and Miriam Balderas for lab support. Finally, the 
authors thank Peter Calkins, Jennifer Spinler, Yea Ping Lin, and Jeremy Pena 
for their insightful commentaries.
References
1. Fuller R: Probiotics in man and animals.  J Appl Bacteriol 1989,
66(5):365-378.
2. FAO/WHO: Health and Nutritional Properties of Probiotics
in Food including Powder Milk with Live Lactic Acid Bacte-
ria. Report of the Joint Food and Agriculture Organization
(FAO) of the United Nations/World Health Organization
(WHO) Expert Consultation on Evaluation of Health and
Nutritional Properties of Probiotics in Food Including Pow-
der Milk with Live Lactic Acid Bacteria.  2001
[http:www.who.int/foodsafety/publications/fs_management/en/
probiot ics.pdf].
3. Abrahamsson TR, Jakobsson T, Bottcher MF, Fredrikson M, Jenmalm
MC, Bjorksten B, Oldaeus G: Probiotics in prevention of IgE-
associated eczema: a double-blind, randomized, placebo-
controlled trial.  J Allergy Clin Immunol 2007, 119(5):1174-1180.
4. Shornikova AV, Casas IA, Isolauri E, Mykkanen H, Vesikari T: Lacto-
bacillus reuteri as a therapeutic agent in acute diarrhea in
young children.  J Pediatr Gastroenterol Nutr 1997, 24(4):399-404.
5. Shornikova AV, Casas IA, Mykkanen H, Salo E, Vesikari T: Bacterio-
therapy with Lactobacillus reuteri in rotavirus gastroenteritis.
Pediatr Infect Dis J 1997, 16(12):1103-1107.
6. Saunders S, Bocking A, Challis J, Reid G: Effect of Lactobacillus
challenge on Gardnerella vaginalis biofilms.  Colloids Surf B Bio-
interfaces 2007, 55(2):138-142.
7. Savino F, Pelle E, Palumeri E, Oggero R, Miniero R: Lactobacillus reu-
teri (American Type Culture Collection Strain 55730) versus
simethicone in the treatment of infantile colic: a prospective
randomized study.  Pediatrics 2007, 119(1):e124-130.
8. Tubelius P, Stan V, Zachrisson A: Increasing work-place healthi-
ness with the probiotic Lactobacillus reuteri: a randomised,
double-blind placebo-controlled study.  Environ Health 2005,
4:25.
9. Imase K, Tanaka A, Tokunaga K, Sugano H, Ishida H, Takahashi S:
Lactobacillus reuteri tablets suppress Helicobacter pylori infec-
tion – a double-blind randomised placebo-controlled cross-
over clinical study.  Kansenshogaku Zasshi 2007, 81(4):387-393.
10. Reuter G: The Lactobacillus and Bifidobacterium microflora of
the human intestine: composition and succession.  Curr Issues
Intest Microbiol 2001, 2(2):43-53.
11. Valeur N, Engel P, Carbajal N, Connolly E, Ladefoged K: Coloniza-
tion and immunomodulation by Lactobacillus reuteri ATCC
55730 in the human gastrointestinal tract.  Appl Environ Micro-
biol 2004, 70(2):1176-1181.
12. Jenkinson HF, Lamont RJ: Oral microbial communities in sick-
ness and in health.  Trends Microbiol 2005, 13(12):589-595.
13. Kobayashi H: Airway biofilms: implications for pathogenesis
and therapy of respiratory tract infections.  Treat Respir Med
2005, 4(4):241-253.
14. Bollinger RR, Barbas AS, Bush EL, Lin SS, Parker W: Biofilms in the
normal human large bowel: fact rather than fiction.  Gut 2007,
56(10):1481-1482.
15. Macfarlane S, Dillon JF: Microbial biofilms in the human gas-
trointestinal tract.  J Appl Microbiol 2007, 102(5):1187-1196.
16. Palestrant D, Holzknecht ZE, Collins BH, Parker W, Miller SE, Bol-
linger RR: Microbial biofilms in the gut: visualization by elec-
tron microscopy and by acridine orange staining.  Ultrastruct
Pathol 2004, 28(1):23-27.
17. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H: Spatial
organization and composition of the mucosal flora in
patients with inflammatory bowel disease.  J Clin Microbiol 2005,
43(7):3380-3389.
18. Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K,
Akkermans AD, de Vos WM: Mucosa-associated bacteria in the
human gastrointestinal tract are uniformly distributed along
the colon and differ from the community recovered from
feces.  Appl Environ Microbiol 2002, 68(7):3401-3407.
19. Swidsinski A, Sydora BC, Doerffel Y, Loening-Baucke V, Vanee-
choutte M, Lupicki M, Scholze J, Lochs H, Dieleman LA: Viscosity
gradient within the mucus layer determines the mucosal
barrier function and the spatial organization of the intestinal
microbiota.  Inflamm Bowel Dis 2007, 13(8):963-970.
20. Macfarlane S: Microbial biofilm communities in the gastroin-
testinal tract.  J Clin Gastroenterol 2008, 42(Suppl 3 Pt
1):S142-143.
21. Kleessen B, Blaut M: Modulation of gut mucosal biofilms.  Br J
Nutr 2005, 93(Suppl 1):S35-40.
22. Kleessen B, Kroesen AJ, Buhr HJ, Blaut M: Mucosal and invading
bacteria in patients with inflammatory bowel disease com-
pared with controls.  Scand J Gastroenterol 2002, 37(9):1034-1041.
23. Kleessen B, Hartmann L, Blaut M: Fructans in the diet cause
alterations of intestinal mucosal architecture, released
mucins and mucosa-associated bifidobacteria in gnotobiotic
rats.  Br J Nutr 2003, 89(5):597-606.
24. Macfarlane GT, Furrie E, Macfarlane S: Bacterial milieu and
mucosal bacteria in ulcerative colitis.  Novartis Found Symp 2004,
263:57-64.
25. Pena JA, Li SY, Wilson PH, Thibodeau SA, Szary AJ, Versalovic J: Gen-
otypic and phenotypic studies of murine intestinal lactoba-
cilli: species differences in mice with and without colitis.  Appl
Environ Microbiol 2004, 70(1):558-568.
26. Pena JA, Rogers AB, Ge Z, Ng V, Li SY, Fox JG, Versalovic J: Probi-
otic  Lactobacillus  spp. diminish Helicobacter hepaticus-
induced inflammatory bowel disease in interleukin-10-defi-
cient mice.  Infect Immun 2005, 73(2):912-920.
27. Tannock GW, Ghazally S, Walter J, Loach D, Brooks H, Cook G,
Surette M, Simmers C, Bremer P, Dal Bello F, et al.: Ecological
behavior of Lactobacillus reuteri 100-23 is affected by muta-
tion of the luxS gene.  Appl Environ Microbiol 2005,
71(12):8419-8425.
28. Doleyres Y, Beck P, Vollenweider S, Lacroix C: Production of 3-
hydroxypropionaldehyde using a two-step process with
Lactobacillus reuteri.  Appl Microbiol Biotechnol 2005, 68(4):467-474.
29. Frick JS, Schenk K, Quitadamo M, Kahl F, Koberle M, Bohn E, Aepfel-
bacher M, Autenrieth IB: Lactobacillus fermentum attenuates the
proinflammatory effect of Yersinia enterocolitica on human
epithelial cells.  Inflamm Bowel Dis 2007, 13(1):83-90.
30. Sougioultzis S, Simeonidis S, Bhaskar KR, Chen X, Anton PM, Keates
S, Pothoulakis C, Kelly CP: Saccharomyces boulardii produces a
soluble anti-inflammatory factor that inhibits NF-kappaB-
mediated IL-8 gene expression.  Biochem Biophys Res Commun
2006, 343(1):69-76.
31. Menard S, Candalh C, Bambou JC, Terpend K, Cerf-Bensussan N,
Heyman M: Lactic acid bacteria secrete metabolites retaining
anti-inflammatory properties after intestinal transport.  Gut
2004, 53(6):821-828.
32. Pena JA, Versalovic J: Lactobacillus rhamnosus GG decreases
TNF-alpha production in lipopolysaccharide-activated
murine macrophages by a contact-independent mechanism.
Cellular microbiology 2003, 5(4):277-285.
33. Madara J: Building an intestine-architectural contributions of
commensal bacteria.  N Engl J Med 2004, 351(16):1685-1686.
Additional file 1
Supplementary table. The recipe for the medium, LDMIIIG.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2180-9-35-S1.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Microbiology 2009, 9:35 http://www.biomedcentral.com/1471-2180/9/35
Page 9 of 9
(page number not for citation purposes)
34. Bollinger RR, Everett ML, Palestrant D, Love SD, Lin SS, Parker W:
Human secretory immunoglobulin A may contribute to bio-
film formation in the gut.  Immunology 2003, 109(4):580-587.
35. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke
V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, et al.:
Mucosal flora in inflammatory bowel disease.  Gastroenterology
2002, 122(1):44-54.
36. Lee JH, Del Sorbo L, Khine AA, de Azavedo J, Low DE, Bell D, Uhlig
S, Slutsky AS, Zhang H: Modulation of bacterial growth by
tumor necrosis factor-alpha in vitro and in vivo.  Am J Respir Crit
Care Med 2003, 168(12):1462-1470.
37. Orndorff PE, Devapali A, Palestrant S, Wyse A, Everett ML, Bollinger
RR, Parker W: Immunoglobulin-mediated agglutination of and
biofilm formation by Escherichia coli K-12 require the type 1
pilus fiber.  Infect Immun 2004, 72(4):1929-1938.
38. Zarate G, Nader-Macias ME: Influence of probiotic vaginal lacto-
bacilli on in vitro adhesion of urogenital pathogens to vaginal
epithelial cells.  Lett Appl Microbiol 2006, 43(2):174-180.
39. Talarico TL, Dobrogosz WJ: Chemical characterization of an
antimicrobial substance produced by Lactobacillus reuteri.
Antimicrob Agents Chemother 1989, 33(5):674-679.
40. Cleusix V, Lacroix C, Vollenweider S, Le Blay G: Glycerol induces
reuterin production and decreases Escherichia coli popula-
tion in an in vitro model of colonic fermentation with immo-
bilized human feces.  FEMS microbiology ecology 2008, 63(1):56-64.
41. El-Azizi M, Rao S, Kanchanapoom T, Khardori N: In vitro activity
of vancomycin, quinupristin/dalfopristin, and linezolid
against intact and disrupted biofilms of staphylococci.  Ann
Clin Microbiol Antimicrob 2005, 4:2.
42. Castagliuolo I, Galeazzi F, Ferrari S, Elli M, Brun P, Cavaggioni A, Tor-
men D, Sturniolo GC, Morelli L, Palu G: Beneficial effect of auto-
aggregating  Lactobacillus crispatus on experimentally
induced colitis in mice.  FEMS Immunol Med Microbiol 2005,
43(2):197-204.
43. Walter J, Loach DM, Alqumber M, Rockel C, Hermann C, Pfitzen-
maier M, Tannock GW: D-alanyl ester depletion of teichoic
acids in Lactobacillus reuteri 100-23 results in impaired colo-
nization of the mouse gastrointestinal tract.  Environ Microbiol
2007, 9(7):1750-1760.
44. Mathee K, Ciofu O, Sternberg C, Lindum PW, Campbell JI, Jensen P,
Johnsen AH, Givskov M, Ohman DE, Molin S, et al.: Mucoid conver-
sion of Pseudomonas aeruginosa by hydrogen peroxide: a
mechanism for virulence activation in the cystic fibrosis lung.
Microbiology (Reading, England) 1999, 145(Pt 6):1349-1357.
45. Lin YP, Thibodeaux CH, Pena JA, Ferry GD, Versalovic J: Probiotic
Lactobacillus reuteri suppress proinflammatory cytokines via
c-Jun.  Inflamm Bowel Dis 2008, 14(8):1068-1083.
46. Spinler JK, Taweechotipatr M, Rognerud CL, Ou CN, Tumwasorn S,
Versalovic J: Human-derived probiotic Lactobacillus reuteri
demonstrate antimicrobial activities targeting diverse
enteric bacterial pathogens.  Anaerobe 2008.